Idelalisib for treating chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA359
  • Published: 
Download guidance (PDF)

6 Review of guidance

6.1 The guidance on this technology will be considered for review in September 2018. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
October 2015